Roy Smythe, M.D., is the Chief Executive Officer of SomaLogic, Inc., a leading-edge biotechnology company headquartered in Boulder, Colorado. During the course of his career, he has been an internationally recognized surgeon, biomedical scientist, academician, health system administrator, and healthcare business entrepreneur.
While in medical school at Texas A&M, he was a Charles A. Dana Foundation Scholar at the University of Pennsylvania School of Medicine and the Wharton School of Business. Following medical school, Smythe trained in general surgery, surgical oncology, and thoracic surgery and completed a postdoctoral research fellowship in molecular therapeutics at the University of Pennsylvania. His medical and translational research career then began at the University of Texas MD Anderson Cancer Center, where he was the recipient of NIH and numerous other funding awards. He subsequently chaired the Department of Surgery at Baylor Scott & White Health System and the Texas A&M Health Science Center College of Medicine, where he was the Roney Endowed Chair, and later became the Medical Director of Innovation and Executive Vice President for Institute Development before moving into expanded roles in corporate healthcare.
Smythe came to SomaLogic from Royal Philips, where he served as Global Chief Medical Officer for Strategy and Partnerships. Before joining Philips, he served as Chief Medical Officer at Valence Health, a Chicago-based healthcare company. He held the same title previously at AVIA, a healthcare technology accelerator.
A highly sought-after lecturer and the author of more than 300 papers, abstracts, and essays in academic, literary, and humanities publications, Smythe is also currently a member of more than 20 U.S. national learned societies.